<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863032</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.778</article-id><article-id pub-id-type="other">EPP0695</article-id><article-id pub-id-type="pii">S0924933824007788</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Electroencephalogram monitoring during ketamine antidepressant treatment: a pilot study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fabus</surname><given-names>M. S.</given-names></name><xref rid="aff1850" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0639" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Casey</surname><given-names>D.</given-names></name><xref rid="aff1851" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Warnaby</surname><given-names>K.</given-names></name><xref rid="aff1850" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Woolrich</surname><given-names>M.</given-names></name><xref rid="aff1852" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>McShane</surname><given-names>R.</given-names></name><xref rid="aff1851" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff1852" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff1850"><sup>1</sup>Nuffield Department of Clinical Neurosciences, <institution>University of Oxford</institution></aff><aff id="aff1851"><sup>2</sup>Interventional Psychiatry, <institution>Oxford Health NHS Foundation Trust</institution></aff><aff id="aff1852"><sup>3</sup>Department of Psychiatry, <institution>University of Oxford</institution>, <city>Oxford</city>, <country>United Kingdom</country></aff><author-notes><corresp id="cor0639"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="753">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S378</fpage><lpage>S379</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824007788a.pdf"/><abstract><sec id="sec3841"><title>Introduction</title><p>
Depression is a major cause of disability world-wide. Up to a third of patients have a treatment-resistant form (TRD), presenting a major challenge. Ketamine has been introduced as a novel rapid-acting antidepressant effective in this population. However, at present, ketamine treatment is not routinely informed by any objective neural markers. Basic research has shown promising electroencephalogram (EEG) changes including a decrease in alpha power. However, clinical translation is lacking.</p></sec><sec id="sec3842"><title>Objectives</title><p>Assess the feasibility of identifying EEG correlates of ketamine infusions in a routine outpatient setting with a low-cost, easily usable system.</p></sec><sec id="sec3843"><title>Methods</title><p>The study was carried out at the Oxford Health Foundation Trust Ketamine Clinic (ethics reference 22/EM/0226). N=18 EEG recordings from N=12 patients were collected (5 women, mean age 44, range 33-62, IV dose 0.5-1mg/kg over 40min). 4-channel EEG was collected with a Muse-S headband at 256Hz, from 5min before to 55min after infusion start. 5s epochs were rejected if gyroscope data indicated head movement above 10 deg/s or if amplitude was above 200&#x003bc;V. A spectrogram (4s window, 3s overlap) as well as band-limited power (theta: 4-8Hz, alpha: 8-13Hz, beta: 13-25Hz) were computed. Significance of changes was found with a repeated measures analysis of variance (RM-ANOVA) on power in 5min segments together with post-hoc Tukey&#x02019;s P-values.</p></sec><sec id="sec3844"><title>Results</title><p>Across the ketamine infusion recordings, there was a significant effect of time (F=3.65, P=0.0105) and Channel*Time interaction (F=3.80, P&#x0003c;0.001) on the EEG spectrum. Effects were largest on temporal electrodes, particularly TP9 in the alpha and theta bands (Figure 1, Table 1).<table-wrap position="anchor" id="tab25"><label>Table 1:</label><caption><p>Effect sizes (Cohen&#x02019;s d) and FDR-corrected ANOVA P-values for ketamine effects on each EEG channel and frequency band. P&#x0003c;0.05 was considered significant (bold). n.s. = not significant (P&#x0003e;0.2).</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">
Channel / Band</th><th align="center" valign="middle" rowspan="1" colspan="1">
TP9</th><th align="center" valign="middle" rowspan="1" colspan="1">AF7</th><th align="center" valign="middle" rowspan="1" colspan="1">AF8</th><th align="center" valign="middle" rowspan="1" colspan="1">TP10</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Theta</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>1.16 (P=0.019)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11 (n.s.)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11 (n.s.)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.42 (P=0.113)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Alpha</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold>1.41 (P&#x0003c;0.001)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.12 (n.s.)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.17 (n.s.)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.605 (P=0.113)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Beta</td><td align="center" valign="middle" rowspan="1" colspan="1">1.19 (P=0.112)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03 (n.s.)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.08 (n.s.)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.21 (n.s.)</td></tr></tbody></table><graphic xlink:href="S0924933824007788-FIG0098" position="anchor"/></alternatives></table-wrap></p><p>
<bold>Image:</bold>
</p><p>
<fig position="float" id="fig0098"><graphic xlink:href="S0924933824007788-TABU0025" position="anchor"/></fig>
</p></sec><sec id="sec3845"><title>Conclusions</title><p>In a routine outpatient setting, sub-anaesthetic ketamine infusions in TRD patients were associated with decreased fronto-temporal EEG alpha and theta power. Future work should assess the potential of low-cost routine EEG, and alpha desaturation specifically, to inform individualised ketamine treatment.</p></sec><sec id="sec3846"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>